Regional Differences in Heart Failure With Preserved Ejection Fraction Trials | Circulation
Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction | Hypertension Research
Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries - Journal of Cardiac Failure
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function - ScienceDirect
Heart failure (HF) hospitalisation across 6 major phase 3 trials of... | Download Scientific Diagram
Frontiers | The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study
Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study - Zhou - ESC Heart Failure - Wiley Online Library
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial | Circulation
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial - ScienceDirect
Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review - Vaduganathan - 2016 - European Journal of Heart Failure - Wiley Online Library
Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart Failure | JACC: Heart Failure
Frontiers | Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis
Spironolactone for Heart Failure with Preserved Ejection Fraction | NEJM
Towards precision medicine in heart failure | Nature Reviews Cardiology
Heart failure with preserved ejection fraction: present status and future directions | Experimental & Molecular Medicine
Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Protocols
Machine learning models in heart failure with mildly reduced ejection fraction patients - Frontiers
Under-Enrollment of Obese Heart Failure with Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials - Journal of Cardiac Failure
Data-driven identification of heart failure disease states and progression pathways using electronic health records | Scientific Reports
Detection and Management of Geographic Disparities in the TOPCAT Trial: Lessons Learned and Derivative Recommendations | JACC: Basic to Translational Science
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial | Circulation
Spironolactone Metabolites in TOPCAT — New Insights into Regional Variation | NEJM
Abstract 278: Trends in Prescribing Patterns for Patients Hospitalized With Heart Failure With Preserved Ejection Fraction Before and After Clinical Trial Presentation | Circulation: Cardiovascular Quality and Outcomes
Detection and Management of Geographic Disparities in the TOPCAT Trial: Lessons Learned and Derivative Recommendations - ScienceDirect
PDF) C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial
